Table 3.
Generalized linear model for predicting refractoriness to H1RA
| Characteristics | Odds ratio (95% Cl) | p value |
|---|---|---|
| Age | 1.004 (0.998–1.011) | 0.209 |
| Female | 0.975 (0.827–1.148) | 0.758 |
| BMI | 0.996 (0.973–1.019) | 0.740 |
| Urticaria duration | 1.000 (0.998–1.001) | 0.494 |
| Total IgE | 1.000 (1.000–1.000) | 0.078 |
| UAS7 | 1.008 (1.001–1.016) | 0.020 |
| ASST positivity | 0.971 (0.825–1.142) | 0.720 |
| PAF (≥ 5000 pg/ml) | 1.414 (1.217–1.642) | < 0.001 |
| PAF-AH | 1.000 (0.999–1.002) | 0.582 |
H1RA histamine receptor 1 antagonist, CI confidence interval, BMI body mass index, UAS7 urticaria activity score over 7 days, ASST autologous serum skin test, PAF platelet activating factor, PAF-AH platelet activating factor acetylhydrolase